Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11221971 | 0.87 | CYP2A6 (0.58) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL4231274 | 0.84 | CYP2A6 (0.51) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL11221999 | 0.84 | CYP2A6 (0.51) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL12809334 | 0.84 | RPS6KB2 (0.56) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL6964036 | 0.84 | CYP2A6 (0.54) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL11192747 | 0.81 | ALDH1A1 (0.44) | RAB9ANPC1PKMHPGDNFKB1 | |
| SCHEMBL21622270 | 0.81 | HSP90AB1 (0.47) | RAB9ANPC1PKMHPGDNFKB1 | |
| SCHEMBL1177008 | 0.81 | CYP2A6 (0.58) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL2082131 | 0.80 | RAB9A (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10989411 | 0.80 | AKR1B1 (0.43) | RAB9ANPC1PKMHPGDNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765796-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8552039-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1334956-B1 | Method for preparing sulfone or sulfoxide compound | SUMITOMO CHEMICAL CO (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7662771-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1658273-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6916938-B2 | Method for preparing sulfone or sulfoxide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-07-12 | — | — | US | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20030171589-A1 | Method for preparing sulfone or sulfoxide compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-09-11 | — | — | US | disclosed |
| EP-1334956-A2 | Method for preparing sulfone or sulfoxide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6048852-A | BACTERICIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-11 | — | — | US | disclosed |
| EP-0900197-A1 | BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997030027-A1 | BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-21 | — | — | WO | disclosed |
| EP-0267794-B1 | PROCESS FOR PREPARING POLYOLEFINS | Nippon Petrochemicals Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0267794-A2 | Process for preparing polyolefins | Nippon Petrochemicals Co., Ltd. (JP) | 1988-05-18 | — | — | EP | disclosed |
| US-4525555-A | TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS | NIPPON OIL COMPANY, LIMITED (JP) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | CYP2A6 2689/4885ADRB2 499/4885ASIC3 739/4885 |
| US-20030171589-A1 | Method for preparing sulfone or sulfoxide compound | TST, SDHB, GPX4 | CYP2A6 310/4885ADRB2 4235/4885ASIC3 3158/4885 |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | CYP2A6 2839/4885ADRB2 544/4885ASIC3 746/4885 |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | CYP2A6 2542/4885ADRB2 796/4885ASIC3 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.